Clinical trials: Epirubicin
Breast Cancer, Triple Negative Breast Cancer
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer…
- Trial name
- NCT05909332
- Testing
- Antivascular therapy, Chemotherapy
- Where
- 15 sites in China
- Volunteers
- 764 people
- Sponsor
- Fudan University
Resectable HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and…
- Trial name
- NCT07441460
- Testing
- KN026, HB1801, Trastuzumab
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shanghai JMT-Bio Inc.
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Breast Cancer
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
This study will evaluate the efficacy and safety of treatment with oral capecitabine or intravenous (IV) 5-fluorouracil (5-FU), in combination with epirubicin and cyclophosphamide, prior to surgery in participants with breast…
- Trial name
- NCT02846428
- Testing
- 5-Fluorouracil, Capecitabine, Cyclophosphamide
- Where
- 21 sites in France
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
T Cell Non-Hodgkin's Lymphoma
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide， epirubicin,vindesine, etoposide and prednisone) regimen as…
- Trial name
- NCT02987244
- Testing
- Chidamide, Cyclophosphamide, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and shrink tumors so they can be removed during…
- Trial name
- NCT00008034
- Testing
- capecitabine, cyclophosphamide, epirubicin hydrochloride
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.
- Trial name
- NeoToc (NCT02909751)
- Testing
- Epirubicin 90 mg/m2 iv, Cyclophosphamide 600 mg/m2 iv, Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Vejle Hospital
Triple Negative Breast Cancer
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC.
- Trial name
- NCT01276769
- Testing
- Paclitaxel plus carboplatin, Paclitaxel and epirubicin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Bladder Cancer
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
This is a multicenter, single-arm study to evaluate the efficacy and safety of Pseudomonas aeruginosa the treatment of patients with intermediate and high risk non-muscle invasive bladder cancer.
- Trial name
- NCT05975151
- Testing
- Pseudomonas aeruginosa
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Hospital of Shandong University
Lymphoma,Non-Hodgkin
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.
- Trial name
- NCT02996617
- Testing
- rhG-CSF regimen, Pegylated rhG-CSF regimen
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Shandong Provincial Hospital
Diffuse Large B Cell Lymphoma
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP as first-line treatment of elderly patients with Diffuse large B cell lymphoma
- Trial name
- NCT02767674
- Testing
- Rituximab, Gemcitabine, Oxaliplatin
- Where
- 6 sites in China
- Volunteers
- 258 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Chemotherapy-Induced Neutropenia, Myelosuppression
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection.
- Conditions
- Chemotherapy-Induced Neutropenia, Myelosuppression, Breast Cancer
- Trial name
- MyeloConcept (NCT02692742)
- Testing
- Myelo001
- Where
- 23 sites in Germany
- Volunteers
- 137 people
- Sponsor
- Myelo Therapeutics GmbH
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041262
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 1,300 people
- Sponsor
- Medical Research Council
Breast Cancer
Combination Chemotherapy in Treating Women With Resected Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery.
- Trial name
- NCT00033683
- Testing
- CMF regimen, cyclophosphamide, docetaxel
- Where
- 69 sites in Belgium, United Kingdom
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the…
- Trial name
- NCT00193024
- Testing
- Docetaxel, Epirubicin
- Volunteers
- 90 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer…
- Trial name
- NCT00424606
- Testing
- Docetaxel, Epirubicin
- Where
- 12 sites in Greece
- Volunteers
- 658 people
- Sponsor
- Hellenic Oncology Research Group
Hepatic Carcinoma
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
- Trial name
- NCT04220944
- Testing
- Sintilimab, Microwave Ablation, TACE
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer
Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer
This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF (cyclophosphamide…
- Trial name
- NCT00114816
- Testing
- capecitabine, docetaxel
- Where
- Finland
- Volunteers
- 1,500 people
- Sponsor
- Finnish Breast Cancer Group